Table 1 Demographic and clinical characteristics of patients

Age (years) IQR

46,48 (35,60 − 55,71)

49,04 (38,36–58,87)

0,132*

Follow-up Time (days), IQR

1496,5 (897–2138)

1102 (626–2183)

0,133*

Gender - Male (%)

41 (51,3%)

48 (41,7%)

0,190**

Smoking status

Smoker

21 (26,3%)

41 (35,7%)

0,070**

Non-Smoker

52 (65%)

56 (48,7%)

Ex-Smoker

7 (8,8%)

18 (15,7%)

Body mass index (kg/m²)

28,05 (27,34 − 28,37)

28,05 (25,64 − 30,44)

0,658*

Hypertension

68 (85%)

94 (81,7%)

0,550**

Diabetes mellitus

18 (22,5%)

17(14,8%)

0,167**

Ischemic Heart Disease

2 (2,5%)

4 (3,5%)

0,697**

Heart failure

1 (1,3%)

1 (0,9%)

0,795**

Hypothyroidism

10 (12,5%)

7 (6,1%)

0,118**

Medications Used

- Renin-Angiotensin-Aldosterone-Inhibitor

37 (61,7%)

49 (57%)

0,571**

- Thiazide Diuretics

14 (23,3%)

23 (26,7%)

0,641**

- Spironolactone

4 (2,7%)

3 (5%)

0,162**

- Calcium Channel Blocker

21 (35%)

32 (37,2)

0,785**

- Beta Blocker

25 (41,7%)

27 (31,4%)

0,202**

- Alpha Blocker

5 (8,3%)

12 (14%)

0,298**

- Allopurinol

5 (8,3%)

7 (8,1%)

0,967**

- Sodium bicarbonate

5 (8,6%)

12 (14%)

0,331**

- Polystyrene Sulfonate Calcium

4 (6,8%)

5 (5,8%)

0,813**

- Statin

4 (6,9%)

9 (10,5%)

0,464**

- Metformin

6 (10,3%)

4 (4,8)

0,201**

- Insulin

1 (1,7%)

2 (2,4%)

0,789**

- Anti-aggregant

10 (17,5%)

24 (28,1%)

0,091**

- Anti-coagulant

2 (3,4%)

3 (3,6%)

0,969**

- Proton Pump Inhibitor

6 (10,3%)

11 (13,1%)

0,620**

- Tolvaptan

6 (10,3%)

3 (3,5%)

0,099**